ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
March 19, 2024 08:07 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US.
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
March 12, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro reports 32% growth in fourth quarter as compared to fourth quarter of 2022. Biologics revenue increased 49% YOY.
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
March 11, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces peer-reviewed publication showing correlation of software lesion size to histopathology, only FDA-cleared laser with correlation
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
March 01, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation...
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
February 29, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
February 28, 2024 16:45 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
February 21, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces FDA Clearance and first-in-human cases using 2.2 Software with integrated Maestro Brain Modeling, and publication in NeuroImage
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
January 24, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
First successful procedure with ClearPoint Prism Neuro Laser Therapy System and Neuro Navigation System by Kaleida Health in Buffalo.
ClearPoint Neuro tillkännager sin första EU MDR-certifiering och godkännande att skicka produkter till Europa
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (”Företaget”), ett globalt företag inom medicinteknik och cell- och genterapi som erbjuder exakt...
ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces first EU MDR certification success and approval to ship product to Europe from its Carlsbad, California manufacturing facility.